Ensysce Biosciences (ENSC) Stock Price, News & Analysis

Company Overview

Ensysce Biosciences is a clinical-stage specialty pharmaceutical company dedicated to the development of novel prodrug therapies for pain and addiction management. Using its proprietary prodrug technology, the firm aims to improve the safety and efficacy of opioid analgesics by modulating drug release and reducing the potential for abuse. The company’s lead candidates currently in development include a long-acting oral naloxone prodrug for opioid overdose reversal and an extended-release opioid analgesic designed to minimize peak concentrations that can lead to misuse.

Ensysce’s research and development efforts focus on overcoming the inherent limitations of traditional pain medications. By chemically linking active pharmaceutical ingredients to biodegradable carrier molecules, Ensysce seeks to create prodrugs that are inactive until enzymatically or pH-triggered activation in the gastrointestinal tract. This approach not only extends the duration of therapeutic effect but also aims to reduce the appeal of tampering or intravenous abuse. The company’s pipeline also includes combination prodrugs that co-deliver analgesic and antagonist components to further deter misuse.

Established more than a decade ago and headquartered in King of Prussia, Pennsylvania, Ensysce maintains operations primarily in the United States, with research collaborations and licensing agreements reaching into European and Asian markets. The company’s clinical activities have included Phase 1 and Phase 2 studies evaluating safety, pharmacokinetics, and abuse-deterrent properties of its lead compounds. Partnerships with academic institutions and contract research organizations support Ensysce’s preclinical and clinical agenda, laying the groundwork for potential alliances with larger pharmaceutical firms.

Ensysce’s management team brings together seasoned professionals in drug development, regulatory affairs, and commercialization. The executive leadership and board members have backgrounds at major biopharmaceutical and specialty pharmaceutical companies, encompassing expertise in bringing complex formulations through clinical trials and securing regulatory approvals. As the company advances its pipeline, it continues to engage with key opinion leaders and regulatory bodies to align its development programs with evolving standards for abuse-deterrent and long-acting opioid therapies.

Key Stats

• Today's Range: $2.05 to $2.18
• 50-Day Range: $2.02 to $2.55
• 52-Week Range: $1.62 to $14.67
• Volume: 247,662 shs
• Average Volume: 950,834 shs
• Market Capitalization: $5.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Ensysce Biosciences Stock Analysis - MarketRank™

Ensysce Biosciences scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Ensysce Biosciences.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ensysce Biosciences are expected to decrease in the coming year, from ($8.33) to ($12.77) per share.

Price to Book Value per Share Ratio

Ensysce Biosciences has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.49% of the float of Ensysce Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Ensysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ensysce Biosciences has recently decreased by 6.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ensysce Biosciences does not currently pay a dividend.

Dividend Growth

Ensysce Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.49% of the float of Ensysce Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Ensysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ensysce Biosciences has recently decreased by 6.96%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.63

News Sentiment

Ensysce Biosciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Ensysce Biosciences this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.90% of the stock of Ensysce Biosciences is held by insiders.

Percentage Held by Institutions

Only 5.63% of the stock of Ensysce Biosciences is held by institutions.

ENSC Stock Analysis - Frequently Asked Questions

How have ENSC shares performed this year?

Ensysce Biosciences' stock was trading at $8.14 at the start of the year. Since then, ENSC shares have decreased by 73.5% and is now trading at $2.16.

How were Ensysce Biosciences' earnings last quarter?

Ensysce Biosciences, Inc. (NASDAQ:ENSC) issued its earnings results on Tuesday, May, 13th. The company reported ($1.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.02) by $1.63. The company earned $1.32 million during the quarter, compared to analysts' expectations of $0.65 million. Ensysce Biosciences had a negative net margin of 109.49% and a negative trailing twelve-month return on equity of 192.54%.

When did Ensysce Biosciences' stock split?

Shares of Ensysce Biosciences reverse split on the morning of Friday, March 31st 2023.The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Ensysce Biosciences?

Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ensysce Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ensysce Biosciences investors own include Predictive Oncology (POAI), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Meta Platforms (META), Insulet (PODD) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENSC
• CIK: 1716947
• Web: ensysce.com
• Phone: 858-263-4196
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($6.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.99 million
• Net Margins: -109.49%
• Pretax Margin: -109.49%
• Return on Equity: -192.54%
• Return on Assets: -121.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.50
• Quick Ratio: 2.50

Sales & Book Value

• Annual Sales: $5.21 million
• Price / Sales: 0.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.59 per share
• Price / Book: 0.83

Miscellaneous

• Outstanding Shares: 2,370,000
• Free Float: 2,184,000
• Market Cap: $5.12 million
• Optionable: Not Optionable
• Beta: 0.98